A Phase II Trial of Cetuximab Plus Irinotecan as a 2nd-line Treatment in Patients With Metastatic Colorectal Cancer After Failure to Irinotecan That Express Wild-type KRAS With and Without Detectable EGFR Expression
Twenty patients with positive-EGFR results and 20 patients with negative-EGFR results will
be accrued in this study. All patients should have wild-type KRAS.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
South Korea: Korea Food and Drug Administration (KFDA)